Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus | Zendy

Yan Yang | Zendy; Hu Xu | Zendy; Jiandong Wang | Zendy; Xin Wu | Zendy; Wei Wen | Zendy; Yan Liang | Zendy; Lingdi Wang | Zendy; Fengyuan Liu | Zendy; Xiaohui Du | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus

Author(s) -

Yan Yang,

Hu Xu,

Jiandong Wang,

Xin Wu,

Wei Wen,

Yan Liang,

Lingdi Wang,

Fengyuan Liu,

Xiaohui Du

Publication year - 2019

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20190384

Subject(s) - oncolytic virus , oncolytic adenovirus , genetic enhancement , cancer research , breast cancer , adenoviridae , e2f , cancer , biology , virus , in vivo , cancer cell , virotherapy , gene , virology , cell cycle , genetics

The wide application of oncolytic adenovirus presents a novel therapeutic strategy for breast cancer gene therapy. Application of adenovirus alone achieves little curative effects on breast cancer. In addition, it is worth exploring the synergistic anti-tumor effect by inserting immunomodulatory factor in oncolytic adenovirus genome. By taking the advantage of the highly proliferative property of breast cancer, a novel recombinant adenovirus which could selectively kill tumor cells is established under an E2F-1 promoter. Also by carrying human Interleukin-15 (IL-15) gene, the oncolytic adenovirus exhibits an immunomodulatory effect. The present study proved that the novel oncolytic virus (SG400-E2F/IL-15) exhibits an enhanced anti-tumor activity both in vitro and in vivo , representing an experimental basis for breast cancer "virus-gene" therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research